Angiotech corporate partner announces court decision denying preliminary injunctions on drug eluting stents
22 November 2003 - 2:00AM
PR Newswire (US)
Angiotech corporate partner announces court decision denying
preliminary injunctions on drug eluting stents VANCOUVER, Nov. 21
/PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. , the
original developer of the paclitaxel-coated stent technology, today
was notified by its corporate partner, Boston Scientific
Corporation, that the that the U.S. District Court in Wilmington,
Delaware has denied a motion by Cordis Corporation seeking a
preliminary injunction against Boston Scientific's TAXUS(TM)
drug-eluting stent system and has denied a motion by Boston
Scientific seeking a preliminary injunction against Cordis'
CYPHER(TM) drug-eluting stent system. The motions had been brought
in lawsuits in which each of the companies has alleged patent
infringement against the other. Both patent infringement cases
remain pending. Boston Scientific is a worldwide developer,
manufacturer and marketer of medical devices whose products are
used in a broad range of interventional medical specialties.
Angiotech Pharmaceuticals, Inc. is dedicated to enhancing the
performance of medical devices and biomaterials through the
innovative use of pharmacotherapeutics. To find out more about
Angiotech Pharmaceuticals, Inc (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP),
visit our website at http://www.angiotech.com/. Angiotech
Pharmaceuticals Contact: Ian Harper (investors & media) ext.
6933 Rui Avelar (analysts) ext. 6996 Phone: (604) 221-7676
Statements contained herein that are not based on historical or
current fact, including without limitation statements containing
the words "anticipates," "believes," "may," "continue," "estimate,"
"expects," "may" and "will" and words of similar import, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following:
general economic and business conditions, both nationally and in
the regions in which the Company operates; technology changes;
competition; changes in business strategy or development plans; the
ability to attract and retain qualified personnel; existing
governmental regulations and changes in, or the failure to comply
with, governmental regulations; liability and other claims asserted
against the Company; and other factors referenced in the Company's
filings with the United States Securities and Exchange Commission
or the Canadian securities regulators. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements. DATASOURCE:
Angiotech Pharmaceuticals, Inc. CONTACT: Angiotech Pharmaceuticals
Contact: Ian Harper (investors & media) ext. 6933, Rui Avelar
(analysts) ext. 6996, Phone: 604-221-7676
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Angiotech Pharmaceuticals (MM) News-Artikel